MA52629A - Agents inhibiteurs de la tyrosine kinase de bruton - Google Patents

Agents inhibiteurs de la tyrosine kinase de bruton

Info

Publication number
MA52629A
MA52629A MA052629A MA52629A MA52629A MA 52629 A MA52629 A MA 52629A MA 052629 A MA052629 A MA 052629A MA 52629 A MA52629 A MA 52629A MA 52629 A MA52629 A MA 52629A
Authority
MA
Morocco
Prior art keywords
tyrosine kinase
kinase inhibitors
bruton tyrosine
bruton
inhibitors
Prior art date
Application number
MA052629A
Other languages
English (en)
French (fr)
Inventor
Michael Dechantsreiter
Brian T Hopkins
Bin Ma
Isaac Marx
Marta Nevalainen
Robin Prince
Jürgen Schulz
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA52629A publication Critical patent/MA52629A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA052629A 2018-05-14 2019-05-13 Agents inhibiteurs de la tyrosine kinase de bruton MA52629A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862671053P 2018-05-14 2018-05-14

Publications (1)

Publication Number Publication Date
MA52629A true MA52629A (fr) 2021-03-24

Family

ID=67002348

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052629A MA52629A (fr) 2018-05-14 2019-05-13 Agents inhibiteurs de la tyrosine kinase de bruton

Country Status (9)

Country Link
US (1) US10899753B2 (enExample)
EP (1) EP3793994B1 (enExample)
JP (1) JP7359782B2 (enExample)
AR (1) AR115085A1 (enExample)
ES (1) ES2968222T3 (enExample)
MA (1) MA52629A (enExample)
TW (1) TW202016097A (enExample)
UY (1) UY38233A (enExample)
WO (1) WO2019222101A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11820760B2 (en) * 2018-10-15 2023-11-21 Biogen Ma Inc. Crystalline polymorphs of Bruton's tyrosine kinase inhibitors
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
EP4081514A1 (en) * 2019-12-23 2022-11-02 Biogen MA Inc. Btk inhibitors
CN112062691B (zh) * 2020-06-18 2022-12-09 中国农业科学院油料作物研究所 一种柠檬醛苯丁酸肟酯类化合物及其合成方法和应用
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
KR20240128831A (ko) 2021-12-30 2024-08-27 베이진 스위찰랜드 게엠베하 브루톤 티로신 키나아제(btk) 억제제와 e3 리가아제 리간드의 접합에 의한 btk의 분해 및 사용 방법
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
KR20140131955A (ko) 2012-03-09 2014-11-14 카나 바이오사이언스 인코포레이션 신규 트리아진 유도체
EP3444251B1 (en) 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
AU2014362231B2 (en) 2013-12-11 2019-04-04 Biogen Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US20180282310A1 (en) 2015-06-10 2018-10-04 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase

Also Published As

Publication number Publication date
ES2968222T3 (es) 2024-05-08
AR115085A1 (es) 2020-11-25
JP7359782B2 (ja) 2023-10-11
EP3793994B1 (en) 2023-08-23
TW202016097A (zh) 2020-05-01
WO2019222101A1 (en) 2019-11-21
JP2021523206A (ja) 2021-09-02
UY38233A (es) 2019-12-31
US10899753B2 (en) 2021-01-26
US20190382394A1 (en) 2019-12-19
EP3793994A1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
EP3873477A4 (en) CYCLIN DEPENDENT KINASE 7 (CDK7) INHIBITOR
MA53921A (fr) Inhibiteurs de protéine tyrosine phosphatase
IL286462A (en) Protein tyrosine phosphatase inhibitors
EP3844151A4 (en) KRAS G12C INHIBITORS
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
MA42623A (fr) Inhibiteurs de la tyrosine kinase de bruton
EP3414234A4 (en) BRUTON TYROSINE KINASE HEMMER
EP3710439A4 (en) KRAS G12C INHIBITORS
MA43162A (fr) Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton
EP3405192A4 (en) BRUTON TYROSINE KINASE HEMMER
MA52629A (fr) Agents inhibiteurs de la tyrosine kinase de bruton
EP3740206A4 (en) INHIBITORS OF THE CYCLINE-DEPENDENT KINASE 7 (CDK7)
EP3801503A4 (en) INHIBITORS OF SARM1
MA42242A (fr) Inhibiteurs de la tyrosine kinase
MA41350A (fr) Synthèse d'un inhibiteur de la tyrosine kinase de bruton
EP3902805A4 (en) CYCLINE-DEPENDENT KINASE INHIBITORS
MA52813A (fr) Inhibiteurs de sarm1
EP3804707A4 (en) KINASE INHIBITOR
EP3817736A4 (en) PIKFYVE INHIBITORS
MA52809A (fr) Inhibiteurs de sarm1
EP3962908A4 (en) HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
DK3609886T3 (da) Benzoazepinanaloger som inhiberingsmidler for bruton-tyrosinkinase
MA41827A (fr) Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
ZA201906887B (en) Bruton's tyrosine kinase inhibitors